Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.59 |
| ▸ | AKT2 | P31751 | 13/20 | 0.59 |
| ▸ | AKT3 | Q9Y243 | 13/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455669 | 0.93 | AKT1 (0.62) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455684 | 0.93 | AKT1 (0.57) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455763 | 0.93 | AKT1 (0.63) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455820 | 0.91 | AKT1 (0.57) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455630 | 0.90 | AKT1 (0.65) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455792 | 0.89 | AKT1 (0.55) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455731 | 0.89 | AKT1 (0.60) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455561 | 0.88 | AKT1 (0.59) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455836 | 0.88 | AKT1 (0.63) | AKT1AKT2AKT3CYP2C9CYP2C8 | |
| SCHEMBL31455657 | 0.87 | AKT1 (0.65) | AKT1AKT2AKT3CYP2C9CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |